Business Wire

TII

12.8.2024 13:47:19 CEST | Business Wire | Press release

Share
UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture

The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has released a new large language model in its Falcon series, the Falcon Mamba 7B. The new model is the no. 1 globally performing open source State Space Language Model (SSLM) in the world, as independently verified by Hugging Face.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812019509/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture (Photo: AETOSWire)

As the first SSLM for Falcon, it departs from prior Falcon models which all use a transformer-based architecture. This new Falcon Mamba 7B model is yet another example of the pioneering research the institute is conducting and the breakthrough tools and products it makes available to the community in an open source format.

H.E. Faisal Al Bannai, Secretary General of ATRC and Adviser to the UAE President for Strategic Research and Advanced Technology Affairs, said: “The Falcon Mamba 7B marks TII’s fourth consecutive top-ranked AI model, reinforcing Abu Dhabi as a global hub for AI research and development. This achievement highlights the UAE’s unwavering commitment to innovation.”

For transformer architecture models, Falcon Mamba 7B outperforms Meta’s Llama 3.1 8B, Llama 3 8B, and Mistral’s 7B on the newly introduced benchmarks from HuggingFace. Meanwhile for the other SSLMs, Falcon Mamba 7B beats all other open source models in the old benchmarks and it will be the be first model on HuggingFace’s new tougher benchmark leaderboard.

Dr. Najwa Aaraj, Chief Executive of TII, said: “The Technology Innovation Institute continues to push the boundaries of technology with its Falcon series of AI models. The Falcon Mamba 7B represents true pioneering work and paves the way for future AI innovations that will enhance human capabilities and improve lives.”

State Space models are extremely performant at understanding complex situations that evolve over time, such as a whole book. This is because SSLMs do not require additional memory to digest such large bits of information.

Transformer based models, on the other hand, are very efficient at remembering and using information they have processed earlier in a sequence. This makes them very good at tasks like content generation, however, because they compare every word with every other word, this requires significant computational power.

SSLMs can find applications in various fields such as estimation, forecasting, and control tasks. Similar to the transformer architecture models, they also excel in Natural Language Processing tasks and can be applied to machine translation, text summarization, computer vision, and audio processing.

Dr. Hakim Hacid, Acting Chief Researcher of the TII’s AI Cross-Center Unit, said: “As we introduce the Falcon Mamba 7B, I’m proud of the collaborative ecosystem of TII that nurtured its development. This release represents a significant stride forward, inspiring fresh perspectives and further fueling the quest for intelligent systems. At TII, we’re pushing the boundaries of both SSLM and transformer models to spark further innovation in generative AI.”

Falcon LLMs have been downloaded over 45 million times, proving the outstanding success of the models. Falcon Mamba 7B will be released under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812019509/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye